Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Profit After Tax (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Profit After Tax for 6 consecutive years, with -$12.7 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 4.96% to -$12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$48.3 million through Dec 2025, down 75.36% year-over-year, with the annual reading at -$48.3 million for FY2025, 75.36% down from the prior year.
  • Profit After Tax for Q4 2025 was -$12.7 million at Inhibikase Therapeutics, down from -$11.9 million in the prior quarter.
  • The five-year high for Profit After Tax was -$2.6 million in Q2 2021, with the low at -$13.7 million in Q1 2025.
  • Average Profit After Tax over 5 years is -$6.4 million, with a median of -$4.6 million recorded in 2022.
  • The sharpest move saw Profit After Tax tumbled 566.75% in 2021, then grew 15.13% in 2022.
  • Over 5 years, Profit After Tax stood at -$5.0 million in 2021, then increased by 15.13% to -$4.3 million in 2022, then grew by 2.36% to -$4.2 million in 2023, then tumbled by 190.4% to -$12.1 million in 2024, then decreased by 4.96% to -$12.7 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$12.7 million, -$11.9 million, and -$9.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.